(September 21, 2015) A small study found that treatment with the anti-PD-1 immunotherapy nivolumab was able to produce complete responses in patients with advanced platinum-resistant ovarian cancer. The phase II study of 20 patients had an overall response rate of 15% (3 responders); an additional 6 patients had stable disease.
The median progression-free survival time was 3.5 months and the median overall survival time was 20 months.
Results of the clinical trial are published in the Journal of Clinical Oncology. This study is the first to explore the effects of nivolumab against ovarian cancer; the study authors comment that the encouraging safety and clinical efficacy of nivolumab in patients with platinum-resistant ovarian cancer indicate the merit of additional large-scale clinical trials.
Read more about this study in Cancer Network, and read the abstract.
